Edwards Lifesciences Files 8-K Report

TL;DR

Edwards Lifesciences filed a routine 8-K. No major news.

AI Summary

On June 3, 2024, Edwards Lifesciences Corporation filed an 8-K report detailing a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a standard disclosure for Edwards Lifesciences, informing the public of regulatory and financial reporting events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no indication of new material events or risks.

Key Players & Entities

• Edwards Lifesciences Corporation (company) — Registrant
• June 3, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchang
• $4,200,000,000 — Care product group (the "Business") for $4,200,000,000 in cash (the "Transaction"). A copy o

Filing Documents

• d836710d8k.htm (8-K) — 29KB
• d836710dex991.htm (EX-99.1) — 10KB
• g836710g17z64.jpg (GRAPHIC) — 3KB
• 0001193125-24-152323.txt ( ) — 165KB
• ew-20240603.xsd (EX-101.SCH) — 3KB
• ew-20240603_lab.xml (EX-101.LAB) — 17KB
• ew-20240603_pre.xml (EX-101.PRE) — 11KB
• d836710d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "potential," "predict," "expect," "intend," "guidance," "outlook," "optimistic," "aspire," "confident" or other forms of these words or similar expressions and include, but are not limited to, the terms and conditions of the Purchase Agreement, the timing for closing of the Transaction and the Company's ability to satisfy the closing conditions, including the receipt of required antitrust and foreign investment approvals. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, may be outside of the Company's control, and may be subject to the satisfaction of certain customary conditions. The Company's forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Edwards Lifesciences Corporation, dated as of June 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 3, 2024 EDWARDS LIFESCIENCES CORPORATION By: /s/ Linda J. Park Linda J. Park Senior Vice President, Associate General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR